Frank Neumann
Corporate Officer/Principal bei KITE PHARMA INC
Profil
Frank Neumann is currently the Head-Clinical Development at Kite Pharma, Inc. He was previously the Vice President & Head-Oncology Clinical Research at bluebird bio, Inc. and the Chief Medical Officer at Verastem, Inc. He holds a doctorate degree from the University of Bonn and Heinrich-Heine-Universität Düsseldorf.
Aktive Positionen von Frank Neumann
| Unternehmen | Position | Beginn |
|---|---|---|
| KITE PHARMA INC | Corporate Officer/Principal | 01.01.2021 |
Ehemalige bekannte Positionen von Frank Neumann
| Unternehmen | Position | Ende |
|---|---|---|
| VERASTEM, INC. | Technik-/Wissenschafts-/F&E-Leiter | 20.01.2021 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | - |
Ausbildung von Frank Neumann
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
| University of Bonn | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VERASTEM, INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
